CSF2 and fallopian tube cancer: A phase II trial of GM-CSF with weekly protein-bound paclitaxel (AbraxaneTM) as chemoimmunotherapy for platinum-refractory/resistant epithelial ovarian, primary peritoneal, and fallopian tube cancer